Description
ADCC-Enhanced anti-BDCA-2 (BIIB059) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Inflammatory Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced BDCA-2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CLEC4C
Full Name
C-type lectin domain family 4, member C
Background
This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response. The encoded type 2 transmembrane protein may play a role in dendritic cell function. Two transcript variants encoding distinct isoforms have been identified for this gene.
Alternative Names
CLEC4C; C-type lectin domain family 4, member C; DLEC; HECL; BDCA2; CD303; CLECSF7; CLECSF11; PRO3415
Gene ID
170482
UniProt ID
Q8WTT0
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CLEC4C include Cardiomyopathy, Dilated, 1C, With Or Without Left Ventricular Noncompaction and Pitt-Hopkins Syndrome.
Related Pathways
Its related pathways are Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) and Innate Immune System.
Function
Lectin-type cell surface receptors may play a role in antigen capture by dendritic cells. It specifically recognizes the galactose-terminal non-sialic acid bis-antennary glycan containing trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binding to serum IgG. Effectively target the ligand into the compartment for antigen processing and peptide loading, and then present it to T cells. It may mediate the induction and inhibition of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signal receptor to activate protein tyrosine kinases and mobilize intracellular calcium.
Field of research
Immune System antibody
Post-translational modifications
Glycosylation at Asn110, Asn137, and Asn164
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BIIB059
Description
This is an antibody that bind to BDCA2 to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
Antibody Indication
Inflammatory Diseases
